Research Paper Volume 13, Issue 3 pp 4335—4356

CUEDC2 ablation enhances the efficacy of mesenchymal stem cells in ameliorating cerebral ischemia/reperfusion insult

class="figure-viewer-img"

Figure 8. CUEDC2 silencing in MSCs suppresses NF-kB activity following cerebral I/R injury. (A, B) NF-kB and p-NF-kB protein expression in co-cultured neurons as detected by western blotting. (C, D) NF-kB and p-NF-kB protein expression in brain tissues as detected by western blotting. (E) TNF-α level in co-cultured neurons as detected by ELISA assay. (F) TNF-α level in brain tissues as analyzed by ELISA assay. (G) IL-1β level in co-cultured neurons as determined by ELISA assay. (H) IL-1β level in brain tissues as analyzed by ELISA assay. (I) IL-6 level in co-cultured neurons as evaluated by ELISA assay. (J) IL-6 level in brain tissues as determined by ELISA assay. CTR: control; CUEDC2: CUE domain-containing 2; OGD/R: oxygen-glucose deprivation (4 hours) and reperfusion (24 hours). MSCs: mesenchymal stem cells; MSCs-siRNA-CUEDC2: small interfering RNA silencing CUEDC2 in MSCs; MSCs-vector: the vector of MSCs; MCAO, middle cerebral artery occlusion. All data are presented as the mean value ± SD. *p<0.05, **p<0.01; compared to the control, sham and the vector of MSC-group.